unh

Market assumption: DOJ forces divestiture of Optum or material structural separation. Our view: historical precedent in healthcare antitrust strongly favors behavioral remedies (consent decrees, pricing transparency requirements, data firewalls) over forced divestiture. The political cost of dismantling the largest employer-of-physicians in the US is prohibitive...

Market assumption: MLR permanently impaired at 84%+ due to structural post-COVID utilization shift and GLP-1 drug costs. Our view: 70% of the MLR increase is cyclical — driven by care pattern normalization (deferred procedures returning) and a premium repricing lag of 12-18 months. The 30% structural component (GLP-1s, aging demographics) is offset by Optum's ability to manage total cost of care...

Market treats Optum as a cost center or regulatory liability. Reality: Optum generates $22B+ revenue at 8-10% operating margins, growing 12-15% organically. As a standalone entity, Optum would command 20-25x earnings — comparable to Veeva, Evolent, or Agilon...

54M medical members across three segments: Employer & Individual (32M), Medicare Advantage (8.5M, #1 share), and Medicaid/CHIP (8.2M). Commercial membership growing 2-3% through employer wins; MA growing 8-10% on demographic tailwinds. Claims auto-adjudication rate: 87% (industry avg: 78%), enabling lower admin cost per claim...

103M+ served lives through 90,000 affiliated physicians and 4,200 owned care delivery sites. Per-patient-per-month cost runs 15% below fee-for-service average — the core proof point for vertical integration's value. Value-based care arrangements cover > 45% of served lives, with a target of 60% by 2027...

Serves 300+ health plans and 400,000+ physicians with technology, analytics, and managed services. Revenue retention rate: 95%+. Backlog: $33B+ (provides 3+ years of revenue visibility)...

46M members, dominant Blue Cross Blue Shield franchise in 14 states. Carelon (formerly Diversified) is Elevance's answer to Optum — behavioral health, pharmacy, and analytics. But Carelon is 5-7 years behind Optum in scale and integration...

CVS integrated Aetna (2018) to create a payer + PBM + retail pharmacy model. 9,000 retail locations provide physical touchpoints UNH lacks. But CVS's integration has underperformed expectations — Aetna has lost commercial share since acquisition, retail pharmacy is in secular decline, and the company carries $50B+ debt...

Express Scripts (Evernorth) is the #1 PBM by scripts processed. Cigna's strategy: lean into PBM and specialty pharmacy, de-emphasize insurance. Sold individual Medicare business to HCSC (2024)...

The US health insurance market totals approximately $2.9T in premiums. Commercial employer-sponsored: $1.1T (UNH share ~12%). Medicare (including MA): $1.0T (UNH share ~15% of MA)...

The healthcare services market (physician services, ambulatory care, home health, analytics, revenue cycle management) exceeds $2.0T. Optum addresses approximately $600B of this through OptumHealth (care delivery), OptumInsight (analytics/managed services), and adjacent services. Current Optum revenue of ~$175B implies 29% penetration of the addressable services market — significant but with ample room for growth via organic expansion and M&A.

Three primary vectors for TAM expansion: (1) Medicare Advantage enrollment growth — 54% of eligible Medicare beneficiaries are now in MA plans, projected to reach 70% by 2035. (2) Value-based care adoption — OptumHealth's value-based arrangements covering 4.3M patients today vs. 60M+ potential lives...

Optum's clinical and claims data lake spans 230M+ de-identified patient lives with longitudinal records. This is the largest integrated healthcare dataset in the US. It feeds predictive models for clinical risk stratification, utilization forecasting, drug interaction detection, and population health management...

Acquired in 2022 for $13B, Change Healthcare processes 15B+ transactions annually — claims submission, payment integrity, revenue cycle management, and eligibility verification. The platform connects 900K+ physicians, 6K+ hospitals, and 2.4K+ payers. It is critical healthcare infrastructure, which is why the February 2024 ransomware breach was so disruptive and why DOJ scrutiny intensified.

UNH has 300+ AI/ML models in production across three domains: (1) Clinical — ambient clinical documentation (auto-generating visit notes), clinical decision support, care gap identification; (2) Operational — automated prior authorization (reducing turnaround from days to minutes), claims adjudication, fraud detection; (3) Predictive — patient risk scoring, utilization forecasting, drug adherence prediction. The company is investing heavily in generative AI for clinical documentation and member engagement.

UnitedHealthcare contracts with approximately 1.6 million physicians and 7,000 hospitals nationwide, giving it one of the broadest networks in the industry. Beyond contracted access, OptumHealth directly employs or closely affiliates with 90,000+ physicians across 2,000+ locations. This dual model — broad network for member access plus owned physician practices for care management — enables UNH to influence both the demand and supply side of healthcare delivery.

OptumRx is the third-largest US PBM (after CVS Caremark and Express Scripts), managing 1.4B+ prescriptions annually. It has relationships with all major pharmaceutical manufacturers for rebate negotiations and operates specialty pharmacy capabilities handling complex, high-cost medications. Specialty pharmacy is the fastest-growing segment, driven by GLP-1 drugs, oncology biologics, and gene therapies.

UNH owns the entire value chain: insurance underwriting (UnitedHealthcare) feeds patients to owned providers (OptumHealth), whose prescriptions flow through the owned PBM (OptumRx), all connected by the owned data layer (OptumInsight/Change Healthcare). This creates information advantages (seeing claims before competitors), cost advantages (eliminating intermediary margins), and switching costs (clients integrated across multiple Optum services rarely leave). It is the deepest moat in managed care.

DOJ is investigating UNH/Optum vertical integration, particularly the payer-PBM-provider linkage. A negotiated settlement with behavioral remedies (most likely outcome) would remove the largest overhang. Full litigation or forced divestiture is tail risk.

The market is watching for evidence that the medical loss ratio has peaked. Q1 2025 guided 84.0% MLR; any print below 83.5% with stable forward guidance would be taken as confirmation that repricing actions and utilization management are working.

CMS publishes final MA rates in April 2026. The advance notice (Feb 2026) suggested a 3.7% aggregate increase — above medical trend expectations. Final rates above 4% would be a meaningful positive for margins.

Street consensus projects FY2025 EPS of $28.00 on revenue of $435B, reflecting 8.9% revenue growth and modest margin recovery. FY2026 estimates of $31.50 EPS assume MLR normalization to 83.0-83.5% and continued Optum services growth. The revision trend is negative — FY2025 EPS has been cut from $30.50 six months ago, with 28 of 34 analysts revising down.

Bulls (JPMorgan, Goldman Sachs, Barclays) argue: (1) MLR spikes are a normal managed care cycle — repricing actions take 12-18 months to flow through. (2) Medicare Advantage rates are improving. (3) Optum's services growth provides earnings diversification that peers lack...

Bears (Leerink, one Citi analyst) argue: (1) Post-COVID utilization is permanently higher — pent-up demand plus GLP-1 costs are not cyclical. (2) DOJ investigation is serious and could force Optum restructuring. (3) PBM reform is bipartisan and will compress OptumRx margins...

Q4 2024 EPS of $6.42 missed consensus of $6.70 by 4.2%, the largest miss in UNH's modern history. The driver was an 85.2% medical loss ratio, 70bps above guidance, caused by: (1) higher-than-expected flu/RSV season costs, (2) accelerating GLP-1 utilization, (3) catch-up costs from the Change Healthcare disruption backlog. Management guided Q1 2025 to 84.0% MLR, which the market viewed skeptically — the stock dropped 6% on the day.

Even before the Q4 miss, the beat pattern was deteriorating. Average beat declined from +3.6% in 2023 to +2.8% in the first three quarters of 2024. This deceleration reflected progressively higher MLR prints eating into the earnings buffer that management traditionally maintained...

Revenue has consistently met or exceeded expectations — the top line is not the issue. UNH's revenue growth of 10-12% has been durable, driven by Optum services expansion and membership growth. The EPS pressure is entirely a margin story: MLR compression consuming operating leverage...

CFO John Rex sold $8M in UNH shares in February 2025 under a pre-arranged 10b5-1 plan. While planned sales are routine, the timing — during a period of DOJ uncertainty and post the Q4 miss — has drawn attention. No other C-suite insiders have made open-market purchases in the past 12 months...

Top institutional holders — Vanguard (8.4%), BlackRock (7.1%), State Street (4.3%) — have maintained positions with minimal changes. No major institutional exits in the most recent 13F filings. Wellington Management trimmed by 8%, and T...

UNH's 5-year CDS spread widened 15bp following the DOJ probe announcement, from 45bp to 60bp. This is a modest widening that reflects increased uncertainty rather than distress — UNH remains solidly investment-grade (A+/A1). Bond spreads on the company's $40B+ debt are 85-120bp over Treasuries, up from 60-90bp pre-DOJ...

In 2018, the DOJ challenged the CVS-Aetna vertical merger on antitrust grounds — the closest precedent to the current UNH/Optum investigation. The case settled with behavioral remedies (Aetna divested its Medicare Part D business). The settlement took 14 months from initial challenge to resolution...

The Affordable Care Act passage in 2010 was widely expected to be devastating for managed care companies. UNH dropped 30% during the legislative debate period (2009-2010). However, the ACA ultimately expanded the addressable market: Medicaid expansion added millions of new members, and the insurance exchanges created new distribution channels...

In the late 1990s, managed care companies faced a public backlash over HMO practices — denials, restricted networks, and perceived rationing of care. MLR spiked industry-wide as companies loosened restrictions to reduce political pressure. Several smaller insurers were acquired or went bankrupt...

Background: CEO of GlaxoSmithKline (2008-2017), where he oversaw a strategic pivot from blockbuster drugs to diversified healthcare. Joined UNH as Optum CEO in 2018, elevated to group CEO in February 2024 after Thompson's assassination. Strengths: deep understanding of Optum (the growth engine), global healthcare perspective, crisis management capability...

The continuity anchor. Rex has served as CFO since 2016 and overseen UNH's capital allocation through the Change Healthcare acquisition ($13B), aggressive buyback program ($12.5B/year), and 15% annual dividend growth. He maintained investment-grade credit through the acquisition spree while keeping debt/equity below 0.8x...

Dirk McMahon serves as COO, overseeing day-to-day operations across both UnitedHealthcare and Optum. Previously CEO of UnitedHealthcare, he brings deep payer-side expertise that complements Witty's Optum background. McMahon is widely viewed as an internal CEO successor candidate if Witty steps down...

In a recession, UNH experiences enrollment mix shift rather than demand destruction. Commercial members lose employer coverage and shift to Medicaid (lower margin) or ACA exchanges (moderate margin). Historical pattern: in 2008-2009, UNH lost ~2M commercial members but gained ~1.5M Medicaid members...

UNH carries $61B in total debt at an average cost of ~3.8%. With $15B in maturities through 2027, refinancing at current market rates (5.5-6.0% for investment-grade 10-year) increases annual interest expense by $400-600M. Each 100bp increase in refinancing rates adds ~$150M in annual interest expense (~$0.13/share after tax)...

Medical cost inflation consistently runs 2-3 percentage points above CPI. Drivers: technology adoption (higher-cost procedures), pharmaceutical pricing (especially specialty/GLP-1s), labor costs (nurse/physician wage inflation), and demographic aging. UNH offsets through: (1) premium repricing with a 12-18 month lag, (2) Optum's cost management reducing total cost of care, (3) network negotiation leverage from 54M covered lives...

UNH loads positively on value (+0.4), quality (+0.6), and low volatility (+0.3), consistent with its profile as a profitable, low-beta mega-cap. The negative momentum loading (-0.5) is a recent development driven by the 35% drawdown from the all-time high. Historically, UNH had positive momentum exposure (+0.3 average over the prior 5 years)...

UNH correlates 0.65 with the S&P 500 and 0.82 with XLV (Health Care Select ETF). The relatively lower S&P correlation provides portfolio diversification value, while the high XLV correlation means UNH moves largely with the healthcare sector. Cross-asset: negatively correlated with 10Y Treasury yields (-0.25), which is unusual for equities and reflects the rate sensitivity of insurance investment portfolios.

Realized 30-day volatility is 24%, well above the 5-year average of 18%. The volatility expansion began with the CEO assassination (December 2024) and was sustained by the Q4 earnings miss and DOJ news. The vol-of-vol is also elevated, meaning day-to-day volatility is itself unpredictable...

30-day IV at 32% is in the 78th percentile of the past 12 months. The IV term structure is in contango (longer-dated options are even more expensive), which is unusual and reflects the market pricing elevated uncertainty through year-end — specifically around DOJ resolution timing. The 90-day IV is 35% and 180-day IV is 33%, suggesting the market expects peak uncertainty in the 3-6 month window.

The 25-delta put implied volatility is 8% above the 25-delta call IV, indicating significant demand for downside protection relative to upside participation. This skew is ~2x the normal level for UNH and comparable to skews seen during acute regulatory events (e.g., ACA passage debates in 2009-2010). The steep skew suggests institutional hedging activity rather than speculative put buying.

Two clusters of unusual activity detected: (1) Large put spreads at $380/$350 strikes for June 2025 expiry — approximately $45M in notional, likely institutional hedges against a DOJ worst-case scenario. (2) Call buying at the $500 strike for December 2025 expiry — approximately $20M in notional, likely positioning for a DOJ resolution rally. The two-sided activity confirms the market is pricing a binary outcome.

The board consists of 13 directors, 12 of whom qualify as independent under NYSE listing standards. Lead independent director Gail Wilensky brings deep healthcare policy expertise (former HCFA administrator). The board includes former executives from Dow, General Mills, and Microsoft, providing cross-industry strategic perspective...

Following the December 2024 assassination of CEO Brian Thompson, the board undertook an accelerated refresh. Two new directors were added in Q1 2025 — one with healthcare operations background, one with cybersecurity expertise (relevant post-Change Healthcare breach). While the additions are sensible, the rapid turnover introduces a settling-in period during a critical juncture for the company.

Four standing committees: Audit, Compensation, Nominating/Governance, and Public Policy. All chaired by long-tenured independent directors. The Public Policy Committee has taken on elevated importance given DOJ scrutiny and PBM reform debates...

PE: 16.8x (threshold: 1.5) — FAIL, but insurance float dynamics make traditional liquidity metrics misleading. Earnings stability: positive EPS every year for 15+ years — PASS. Dividend record: 15 consecutive years of increases — PASS...

Durable competitive advantage: YES — the only company with scale across payer + provider + PBM + analytics. No competitor can replicate the integrated model. Predictable earnings: YES — 14% EPS CAGR over 10 years with no negative-growth years...

ROIC: 15.4% — top quartile of S&P 500 and top decile of healthcare sector. EV/EBIT: 14.1x — below sector median of 18x. Combined ranking places UNH in the top decile of the Magic Formula universe...